Patient P-01722
Synthetic patientNBL-101 · Day 113 · 55–64 · M · baseline S09Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Declining
Discontinuation risk
14%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S09
- Day 78 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 78.
Primary contributors, last 14 days
- GI instability-7
- Nutritional resilience-6
- Inflammatory activity-5
- Toxicity+4
- Treatment adherence-3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion11.6/100
improving · -2.7 vs previous 14 d
Toxicity
Blood20/100
improving · -3.0 vs previous 14 d
Sleep quality
Wearable52.5/100
stable · -0.5 vs previous 14 d
Energy level
Daily log6/10
improving · +0.5 vs previous 14 d
Stress level
Daily log3.9/10
improving · -0.2 vs previous 14 d
Steps
Wearable8,288
stable · -79 vs previous 14 d
Adherence
Companion80.4 %
worsening · -8.2 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 74 from the failing basin, 43 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
Main detractors to watch
- Poor metabolizerhidden · steering -12.7
- IL6 high-expression varianthidden · steering -7.3
- Spicy / capsaicinperturbation · steering -3.9
- Poor-sleep weekperturbation · steering -3
- Spicy / capsaicindetractor · GI +2 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Spicy / capsaicin+2detractor · 77%
- Histamine load-1.1no signal · 36%
- Insoluble fibre+0.6no signal · 20%
- Alcohol-0.4no signal · 15%
- Simple carbohydrates+0.3no signal · 15%
- Dietary fat load+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 4 · butyrate capacity 81/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 39 ms
- Sleep
- 7.5 h
- Steps
- 7,938
- Resting HR
- 68 bpm
Daily log: GI score 12, nutritional resilience 64, adherence 80.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01313 | 45% | S01 | BR-03 | improved | 32 |
| P-01320 | 40% | S09 | HY-01 | improved | 38 |
| P-01346 | 37% | S12 | DT-01 | improved | 52 |
| P-01618 | 36% | S10 | GI-04 | improved | 39 |
| P-01731 | 35% | S01 | ME-01 | improved | 32 |
| P-01342 | 34% | S11 | DT-01 | improved | 48 |
| P-01593 | 34% | S10 | HY-01 | improved | 56 |
| P-01752 | 34% | S20 | DT-01 | improved | 50 |
| P-01773 | 34% | S05 | AD-05 | improved | 27 |
| P-01861 | 34% | S12 | HY-01 | improved | 47 |
| P-01374 | 33% | S08 | HY-01 | improved | 49 |
| P-01385 | 33% | S06 | HY-01 | improved | 50 |